Hemorragia alveolar asociada con tirofiban

Alexander Aguilar Arias; Carlos Arturo  Martínez; Ana María  Arango; Sara  Vélez Garcés; Catalina  Aguilar Arias

Alveolar hemorrhage associated with tirofiban

Hemorragia alveolar asociada con tirofiban

Published 2023-03-22

Open | Download

PDF (Spanish) FLIP

Issue

Pre-Print

Section

Case Reports

How to Cite

Aguilar Arias, A., Martínez, C. A. ., Arango, A. M. ., Vélez Garcés, S. ., & Aguilar Arias, C. (2023). Alveolar hemorrhage associated with tirofiban. Journal of Medicine and Surgery Repertoire. https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/1427

DOI

license

Alexander Aguilar Arias

UPB-CEDIMED

https://orcid.org/0000-0001-9186-4135

Carlos Arturo Martínez

Clínica CardioVID

https://orcid.org/0000-0003-3748-2368

Ana María Arango

Clínica Las Américas

https://orcid.org/0000-0001-9398-5715

Sara Vélez Garcés

Clínica CES

https://orcid.org/0000-0002-6729-685X

Catalina Aguilar Arias

UPB-CEDIMED

https://orcid.org/0000-0002-5651-5383

Show authors biography

Alexander Aguilar Arias,

Residente de Radiología e Imágenes Diagnósticas UPB-CEDIMED, Medellín, Colombia.

Catalina Aguilar Arias,

Estudiante de Medicina. Universidad Pontificia Bolivariana. Medellín, Colombia.

We present the case of a patient with alveolar hemorrhage associated with tirofiban whose diagnosis was delayed because the initial signs went unnoticed, initially interpreting the condition as pneumonia. Early and accurate diagnosis is essential to guide the management of any type of bleeding complication in a patient with acute coronary syndrome (ACS), especially in the case of alveolar hemorrhage (AH).

Article visits 157 | PDF visits 112

Downloads

Download data is not yet available.

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87-165. https://doi.org/10.1093/eurheartj/ehy394.
Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367. https://doi.org/10.1093/eurheartj/ehaa575.
Hu X, Wang W, Ye J, Lin Y, Yu B, Zhou L, Zhou Y, Dong H. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon. Biomed Pharmacother. 2021;143:112196. https://doi.org/10.1016/j.biopha.2021.112196.
Bor WL, Zheng KL, Tavenier AH, Gibson CM, Granger CB, et al. Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction. EuroIntervention. 2021;17(5):e401-e410. https://doi.org/10.4244/EIJ-D-21-00287.
Karathanos A, Lin Y, Dannenberg L, et al. Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis. Can J Cardiol. 2019;35(11):1576-1588. https://doi.org/10.1016/j.cjca.2019.05.003.
Zhou X, Peng H, Yin Y, Huang H, Zeng J, Ouyang F. Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia. International Journal of Cardiology. 2016;206:93-94. https://doi.org/10.1016/j.ijcard.2016.01.020.